Lutetium Lu 177 vipivotide tetraxetan: complete guide

Lutetium Lu 177 vipivotide tetraxetan (PSMA-617) is a radioligand therapy first approved by FDA as Pluvicto in 2022. This guide covers its structure, mechanism, labeled uses, trials and warnings.

Complete guide5 min read

Key takeaway

FDA first approved Pluvicto on March 23, 2022, with new indications added in 2025 and 2026. In the VISION trial, median overall survival was 15.3 months with Pluvicto plus standard care versus 11.3 months with standard care alone. The label gives its molecular mass as 1,216.06 g/mol.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Pluvicto on March 23, 2022.” (this article)
ClassPeptide science
Studies cited3 in this article · 3 across 1 article on Lutetium Lu 177 vipivotide tetraxetan
Related productsResearch peptide catalog

Lutetium Lu 177 vipivotide tetraxetan is a radioactive prostate cancer drug built on a small peptide-like molecule. That molecule binds PSMA, a protein on prostate cancer cells. It is better known as PSMA-617, and it is sold as Pluvicto. This guide covers its structure, mechanism, approvals, trials and warnings, with sources checked on November 17, 2026.

Quick answer: Lutetium Lu 177 vipivotide tetraxetan is a prescription radioligand therapy for PSMA-positive metastatic prostate cancer in adults. Its label now covers both hormone-sensitive and hormone-resistant disease, in specific settings. It has no boxed warning. Key warnings include radiation exposure, low blood counts, kidney toxicity, fetal harm and infertility.

Vitrapep does not sell lutetium Lu 177 vipivotide tetraxetan; this page is a reference summary of published research and regulatory information.

What is lutetium Lu 177 vipivotide tetraxetan?

The Pluvicto label calls it “a radioligand therapeutic agent.” It adds: “Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177” (Pluvicto label, 2026). A ligand is a molecule that binds a target. A chelator is a cage-like molecule that holds a metal atom.

The targeting part is peptide-like rather than a classic peptide. Its developers called it a “peptidomimetic structure” made “by solid-phase peptide chemistry” (Benešová et al., 2015). PubChem’s chemical name shows glutamic acid joined by a urea bridge to a lysine unit. A naphthylalanine and a cyclohexane spacer then link to the DOTA ring (PubChem CID 122706786). Our page on types of peptides covers peptide-like molecules.

The label gives the formula C49H68(177)LuN9O16 and a molecular mass of 1,216.06 g/mol. Drugs@FDA lists the original approval of Pluvicto on March 23, 2022, under NDA 215833, held by Novartis (Drugs@FDA).

Table 1

Lutetium Lu 177 vipivotide tetraxetan: key facts

Fact Detail
Structure type Peptidomimetic PSMA-binding ligand (glutamate-urea-lysine core with a naphthylalanine and cyclohexane linker) plus a DOTA chelator holding lutetium-177
Class Radioligand therapeutic agent
Molecular formula C49H68(177)LuN9O16 (label)
Molecular weight 1,216.06 g/mol (label)
First FDA approval March 23, 2022 (Pluvicto, NDA 215833)
Brand names (US) Pluvicto

How does lutetium Lu 177 vipivotide tetraxetan work?

PSMA stands for prostate-specific membrane antigen. The label describes the radioactive lutetium-177 as “linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.” The beta-minus emission from lutetium-177 then delivers radiation to PSMA-expressing cells and nearby cells. The resulting DNA damage can lead to cell death (Pluvicto label, 2026).

The early lab work explains the design. In cell experiments, PSMA-617 bound PSMA tightly and was efficiently taken up into PSMA-positive prostate cancer cells. In mice carrying human prostate tumors, it gave high tumor-to-background contrast (Benešová et al., 2015). Those were in vitro and animal data. The same targeted radiation idea underlies lutetium Lu 177 dotatate, which targets somatostatin receptors instead.

What is lutetium Lu 177 vipivotide tetraxetan approved for?

The current Pluvicto label lists two indications for adults with PSMA-positive metastatic prostate cancer:

  • in combination with androgen receptor pathway inhibitor (ARPI) therapy, for metastatic “androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer”; and
  • for metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer in patients already treated with ARPI therapy, who either are considered appropriate to delay taxane-based chemotherapy or have received it.

Drugs@FDA lists new indication approvals on March 28, 2025, and July 31, 2026 (Drugs@FDA). Androgen pathway modulation refers to hormone therapy that blocks androgen signaling.

What did the key trials show?

VISION. This open-label phase 3 human trial randomized 831 men with metastatic castration-resistant prostate cancer. All had already received hormone therapy and a taxane. It compared Pluvicto plus standard care with standard care alone (NCT03511664). Median imaging-based progression-free survival was 8.7 versus 3.4 months (hazard ratio 0.40). Median overall survival was 15.3 versus 11.3 months (hazard ratio for death 0.62). Grade 3 or higher adverse events occurred in 52.7% versus 38.0% (Sartor et al., 2021).

PSMAfore. This phase 3 trial randomized 468 taxane-naive patients to Pluvicto or a change of ARPI drug. Median radiographic progression-free survival was 9.30 versus 5.55 months (hazard ratio 0.41). Grade 3 to 5 adverse events occurred in 36% versus 48% (Morris et al., 2024; NCT04689828). The label reports no significant overall survival difference.

PSMAddition. This randomized, open-label trial enrolled patients with hormone-sensitive disease. It compared Pluvicto plus ARPI (572 patients) with ARPI alone (572). The label reports a radiographic progression-free survival hazard ratio of 0.72 (p = 0.002). Overall survival data were immature (NCT04720157).

What side effects does the label list?

The Pluvicto label has no boxed warning. Across a pooled safety population of 1,320 patients, the most common adverse reactions and lab abnormalities included:

  • decreased lymphocytes (86%);
  • decreased hemoglobin (68%);
  • fatigue (51%);
  • dry mouth (46%);
  • decreased neutrophils (35%) and nausea (35%); and
  • decreased platelets (33%).

Other common lab changes included a drop in kidney function (eGFR, 28%) and raised AST (25%). The warnings section covers radiation exposure, myelosuppression (low blood counts), kidney toxicity, harm to a fetus and infertility (Pluvicto label, 2026).

What is lutetium Lu 177 vipivotide tetraxetan’s regulatory status, and how is it used in research?

Pluvicto is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription, with Novartis as the holder. Its label has been revised as trials reported, most recently in July 2026.

Research has moved the drug earlier in the course of prostate cancer. VISION studied it after hormone therapy and chemotherapy. PSMAfore studied it before chemotherapy, and PSMAddition studied it in hormone-sensitive disease. ClinicalTrials.gov lists PSMAddition as active, not recruiting, with completion expected in August 2028.

Frequently asked questions about lutetium Lu 177 vipivotide tetraxetan

Is Pluvicto a peptide?

Not a classic one. Its targeting part is a peptidomimetic, a peptide-like molecule built with peptide chemistry, joined to a DOTA chelator.

What is PSMA-617?

It is the research name for vipivotide tetraxetan, the PSMA-binding ligand plus chelator in Pluvicto.

When was Pluvicto approved?

Drugs@FDA lists the original approval of Pluvicto on March 23, 2022.

Did Pluvicto improve survival?

In VISION, yes: median overall survival was 15.3 versus 11.3 months. In PSMAfore, the label reports no significant overall survival difference.

Does it have a boxed warning?

No. Its warnings cover radiation exposure, low blood counts, kidney toxicity, fetal harm and infertility.

What to know now

  • Structure: peptidomimetic PSMA ligand plus DOTA chelator plus lutetium-177; 1,216.06 g/mol.
  • Approval: Pluvicto, March 23, 2022; new indications in 2025 and 2026.
  • Mechanism: binds PSMA; beta emission damages DNA in nearby cancer cells.
  • Label: PSMA-positive metastatic prostate cancer in adults, in defined settings.
  • Evidence: VISION overall survival 15.3 vs 11.3 months; PSMAfore progression hazard ratio 0.41.
  • Safety: no boxed warning; low blood counts, fatigue and dry mouth are common.

What we’re watching

Mature overall survival data from PSMAddition, which ClinicalTrials.gov lists as active, not recruiting. Further Pluvicto label revisions on DailyMed, last revised in July 2026. Related guides: lutetium Lu 177 dotatate and gallium Ga 68 dotatate.

Sources: Novartis Pharmaceuticals Corporation 2026, PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 215833 (PLUVICTO) . Retrieved November 17, Drugs@FDA: NDA 215833 (PLUVICTO); National Center for Biotechnology Information 2026, PubChem compound summary for CID 122706786, vipivotide tetraxetan; Benešová 2015, Journal of Nuclear Medicine, 56; Sartor 2021, The New England Journal of Medicine, 385; Endocyte 2018, Study of 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer (VISION); Morris 2024, The Lancet, 404; Novartis Pharmaceuticals 2020; Novartis Pharmaceuticals 2021. All 9 citations

Back to the research library

References

  1. Novartis Pharmaceuticals Corporation. (2026). PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) prescribing information (revised 7/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 215833 (PLUVICTO). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 122706786, vipivotide tetraxetan. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/122706786
  4. Benešová, M., et al. (2015). Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. Journal of Nuclear Medicine, 56(6), 914-920. https://doi.org/10.2967/jnumed.114.147413
  5. Sartor, O., et al. (2021). Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. The New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322
  6. Endocyte. (2018). Study of 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer (VISION) (ClinicalTrials.gov ID NCT03511664). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03511664
  7. Morris, M. J., et al. (2024). 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. The Lancet, 404(10459), 1227-1239. https://doi.org/10.1016/S0140-6736(24)01653-2
  8. Novartis Pharmaceuticals. (2020). 177Lu-PSMA-617 vs. androgen receptor-directed therapy in the treatment of progressive metastatic castrate resistant prostate cancer (PSMAfore) (ClinicalTrials.gov ID NCT04689828). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04689828
  9. Novartis Pharmaceuticals. (2021). An international prospective open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with standard of care (SoC), versus SoC alone, in adult male patients with metastatic hormone sensitive prostate cancer (mHSPC) (PSMAddition) (ClinicalTrials.gov ID NCT04720157). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04720157